BJH - volume 7, issue Abstract Book BHS, january 2016
H. Maes , J. Maertens MD, PhD, S. Smits , E. Lierman PhD, N. Boeckx MD, PhD, T. Tousseyn MD, PhD, G. Verhoef MD, PhD, P. Vandenberghe MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
C. AL Assaf , F. Van Obbergh MD, J. Billiet MD, E. Lierman PhD, T. Devos MD, PhD, C. Graux MD, PhD, A.S. Hervent , T. Tousseyn MD, PhD, P. De Paepe MD, PhD, P. Papadopoulos , L. Michaux MD, PhD, P. Vandenberghe MD, PhD
BJH - volume 6, issue Abstract Book BHS, january 2015
P. Vandenberghe MD, PhD, I. Wlodarska , T. Tousseyn MD, PhD, L. Dehaspe , D. Dierickx MD, PhD, M. Verheecke , A. Uyttebroeck MD, PhD, O. Bechter , M. Delforge MD, PhD, V. Vandecaveye , N. Brison , G.E.G. Verhoef , E. Legius , F. Amant , J.R. Vermeesch
BJH - volume 5, issue 1, march 2014
N. Put MD, PhD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD
Chronic mature B-cell lymphoproliferative disorders, i.e. B-cell chronic lymphocytic leukaemia and plasma cell dyscrasias such as multiple myeloma, have a variable disease course. Clinical staging systems and several biological parameters have been used to estimate tumour burden and predict prognosis. In addition, cytogenetic aberrations have prognostic significance and are therefore investigated in the routine evaluation of these diseases. In this doctoral study, we evaluated available techniques, which can be applied to detect cytogenetic abnormalities in the routine investigation of chronic lymphocytic leukaemia and multiple myeloma. Next, we characterised cytogenetic entities, in particular translocations involving immunoglobulin genes and the proto-oncogenes BCL2 and MYC and investigated clonal evolution in chronic lymphocytic leukaemia.
(BELG J HEMATOL 2014;5(1):25–30)
Read moreBJH - volume 5, issue 1, march 2014
N. Put MD, PhD, L. Michaux MD, PhD, P. Vandenberghe MD, PhD
The presence, number and/or type of chromosomal aberrations represent an independent predictor of prognosis in several haematological disorders. Therefore, (cyto)genetic analysis is now routinely performed in many haematological malignancies. Different techniques are available to detect chromosomal abnormalities. Conventional cytogenetic analysis can be performed, and also interphase fluorescent in situ hybridisation is widely used. In addition, multiplex ligation-dependent probe amplification and more recently analysis by means of different array-platforms have been used in research and routine setting. Newly developed techniques, such as next-generation sequencing are only available for research purposes thus far. All these techniques are complementary, and each technique has its own (dis)advantages.
(BELG J HEMATOL 2014;5(1):3–11)
Read moreBJH - volume 5, issue Abstract Book BHS, january 2014
C. AL Assaf , E. Lierman PhD, T. Devos MD, PhD, C. Graux MD, PhD, J. Billiet MD, J. Finalet Ferreiro , P. Vandenberghe MD, PhD
BJH - volume 5, issue Abstract Book BHS, january 2014
E. Del Biondo MD, P. Vandenberghe MD, PhD, B. Dewaele , A. Kochuyt , N. Boeckx MD, PhD
Top
